News Santhera preps UK Duchenne drug launch after NICE says yes Santhera will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks after getting the green light for NHS coverage.
News AIs can be used for fracture detection, says NICE NICE has said that four artificial intelligence technologies can be deployed by the NHS to detect fractures on X-rays in urgent care.
News New drugs 'benefit patients, but maybe not populations' The money spent by the NHS on newly approved therapies recommended by NICE might have been better spent elsewhere, according to a new study.
News Price deal opens door to NHS use of Santhera DMD drug Santhera's Duchenne muscular dystrophy (DMD) therapy Agamree has been cleared for NHS use after a confidential pricing agreement.
News Mounjaro cleared for NHS use, but patients may have to wait Many patients can expect a long wait for access to Eli Lilly's obesity shot Mounjaro, even though it has been recommended for routine NHS use by NICE
News NICE backs AZ/Ionis' Wainzua for ATTR polyneuropathy AstraZeneca and Ionis' Wainzua has been recommended for NHS use in the treatment of patients with ATTR polyneuropathy
Market Access Policy in focus: Trump’s Most Favoured Nations drug pricing ... Alice Valder Curran, a partner at Hogan Lovells, provides an update on what's happening right now with Most Favoured Nations drug pricing.
Sales & Marketing FH25: Individual centric investing with Steve Seuntjens In a new FH25 podcast episode, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital.